Biofirm Aerpio Therapeutics secures a $27m series A round, led by Novartis, an existing backer of parent company Akebia.
Biotech firm Aerpio Therapeutics has raised a $27m series A round, led by Novartis BioVentures, a venture unit of Basel-based pharmaceutical company Novartis.
Other investors include early-stage venture firm Venture Investors, life science investor Triathlon Medical Ventures, venture firm Kearny Venture Partners, IT and healthcare investor Athenian Venture Partners, and biofirm investor AgeChem Venture Fund.
The investment is the first of its kind for Cincinnati-based Aerpio; but not for the company it was spun out from in December 2011, Akebia…
